Definium Therapeutics, formerly known as MindMed, is a clinical-stage biopharmaceutical company focused on developing innovative psychedelic-based medicines for psychiatric and neurological disorders. The company specializes in treatments for generalized anxiety disorder, major depressive disorder, PTSD, and other brain health conditions. Its research pipeline includes DT120, an LSD-based investigational therapy, and DT402, an MDMA-derived drug candidate. Definium aims to transform mental healthcare through scientific research, clinical trials, and the development of accessible, effective treatments.